Table 1.
Demographics and disease characteristics of English and Hebrew-speaking Parkinson's patients.
| Variable | English speaking |
Hebrew speaking |
P |
|---|---|---|---|
| n = 250 | n = 233 | ||
| Male sex (%) | 156 (62.4%) | 125 (53.6%) | 0.051 |
| Age, yrs (SD) | 67.9 (9.9) | 65.2 (9.7) | 0.030 |
| Age-at-onset, yrs (SD) | 60.7 (10.7) | 59.5 (10.1) | 0.189 |
| Duration, yrs (SD) | 7.2 (5.1) | 5.8 (5.4) | 0.020 |
| Post-secondary education (%)a | 223 (92.1%) | 164 (70.4%) | <0.001 |
| LRRK2 G2019S mutation carrier (%) | 61 (24.4%) | 62 (26.6%) | 0.578 |
| Levodopa equivalent daily dose, mg (SD) | 383.6 (359.1) | 224.5 (337.5) | <0.001 |
| Total UPDRS-III score (SD)b | 18.3 (10.3) | 20.5 (11.9) | 0.026 |
| GDS score (SD)c | 3.4 (3.2) | 3.7 (3.1) | 0.338 |
| BDI-II score (SD)d | 10.2 (9.2) | 8.6 (6.3) | 0.227 |
| Total MoCA score (SD) | 26.1 (2.4) | 25.4 (2.4) | 0.007 |
Abbreviations: SD, standard deviation; LRRK2, leucine-rich repeat kinase 2; UPDRS-III, Unified Parkinson's Disease Rating Scale, part III (motor); GDS, 15 item Geriatric Depression Scale; BDI-II, Beck Depression Inventory II; MoCA, Montreal Cognitive Assessment.
a
Post-secondary education was available in 475 participants.
b
UPDRS-III was available in 482 participants.
c
GDS score was available in 473 participants.
d
BDI-II score was available in 155 participants.